11 September 2018
A new report by visiongain forecasts the world market for biosimilar monoclonal antibodies (mAbs) will reach $4.1bn in 2020. That revenue prediction and others appear in Biosimilar Monoclonal Antibodies Market Forecast 2016-2026: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab. This report is published in February 2016. Visiongain is a business information publisher and consultancy in London, UK.
The analysis predicts the global biosimilar mAb industry and market will continue to grow at a CAGR of 46.96% from 2015-2020, driven by the biosimilar rituximab and infliximab submarkets. In 2015, the biosimilar rituximab submarket held the highest proportion, holding a market share of 47.2%. This submarket will grow at a CAGR of 31.47% from 2015-2020 and 8.78% from 2020-2026. However, the biosimilar infliximab submarket will become the leading submarket by 2018 and remain as such until 2026. It will also be the fastest growing submarket from 2015-2020 with a CAGR of 60.59%.
Demand for the market will be fuelled by the discounted price biosimilar mAbs are available for in comparison to their reference products. There is a need for cheaper drugs as healthcare budgets become increasingly strained by growing populations and ageing demographics which are associated with a greater prevalence of cancer, amongst other indications.
Robert King, a pharmaceutical industry analyst in visiongain, said:
“There will be a number of high profile originator mAb patent expiries over the next three years creating a growing market for biosimilars in the EU and the US. Revenues in these developed markets will be greater than for revenue in emerging markets. This will occur as the cost of therapy and larger target markets will outweigh the relatively slow rate of adoption. The US will not act as a driver for the market until towards the middle of the forecast period, as a result of later patent expiries there for many leading mAb products”.
This report investigates commercial trends and revenues of the biosimilar mAbs industry from 2016 to 2026, as well as including data from 2015. This report discusses sales potentials of:
• The submarkets of biosimilar mAbs, broken down by applications in the following therapeutic areas:
o Biosimilar rituximab
o Biosimilar infliximab
o Biosimilar trastuzumab
o Biosimilar adalimumab
o Biosimilar bevacizumab
o Biosimilar abciximab
• 17 biosimilar mAb products which are approved across a range of different national markets with different regulatory standards.
• 13 leading national markets such as the US, Japan, EU, Asia Pacific and Rest of the World.
This report qualitatively discusses:
• 10 companies with leading biosimilar mAbs either on the market or in the pipeline in addition to coverage of new M&A and collaborative activity.
• Updated regulatory guidelines for biosimilars in leading national markets such as China, the US and the EU.
• Strengths, weaknesses, opportunities and threats of the biosimilar mAb industry and market.
Our report also features full transcripts of interviews with stakeholders in the market.
Biosimilar Monoclonal Antibodies Market Forecast 2016-2026 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.
19 March 2019
The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.
19 March 2019
With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.
28 February 2019
The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.